Characteristics listed in Table 1 as well as mutations detected in both LSP and PSLP predictive of disease relapse at 2y with P < 0.10 by univariate analysis were International Prognostic Index (IPI) score ≥3 vs. <3 (hazard ratio [HR] 2.3, 95% CI 0.86–6.5, P = 0.098), HGBL vs. DLBCL histology (HR 5.4, 95% CI 1.8–15.7, P = 0.002), double hit lymphoma vs. not (HR 9.0, 95% CI 2.6–30.8, P < 0.001) and CREBBP mutation vs. not (HR 2.6, 95% CI 0.98–7.0, P = 0.054). This evidence concerns the gene CREBBP and high grade B-cell lymphoma.